MicroPET: Radiotracer Imaging of Rodents and Non- Human Primates Alexander K. Converse, PhD University of Wisconsin–Madison Waisman Center - Brain Imaging Core Town Hall - Thursday 2 February 2012
MicroPET: Radiotracer Imaging of Rodents and Non-Human Primates Alexander K. Converse, PhD University of Wisconsin–Madison Waisman Center - Brain Imaging.
Dec 25, 2015
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
MicroPET: Radiotracer Imaging of Rodents and Non-Human Primates
Alexander K. Converse, PhDUniversity of Wisconsin–Madison
Waisman Center - Brain Imaging CoreTown Hall - Thursday 2 February 2012
Radioactive Decay & Positron – Electron Annihilation
Positron Emission Tomography
UW-Madison PET
Animal Brain PET Scanners
6 uL
3 uL
3 uL
2 uL + MR
Fig. 26 BLOOD VOLUME: Carbon monoxide imaging of hemoglobin in rat12
y = 5.05x - 4332y = 6.15x - 5423y = 6.00x - 5264
0
2000
4000
6000
8000
10000
0 1000 2000 3000Cb / CdPu
CdP
u /
CdP
u
AT57AT47AT97
A
y = 5.05x - 4332y = 6.15x - 5423y = 6.00x - 5264
0
2000
4000
6000
8000
10000
0 1000 2000 3000Cb / CdPu
CdP
u /
CdP
u
AT57AT47AT97
A
Fig. 25: QUANTIFICATION: Logan determination of binding of a dopamine
D2 tracer5
PHARMACOKINETIC MODELING
Fig. 24 DOPAMINE RELEASE: Time activity curves of a dopamine D2 receptor tracer in response to
amphetamine5
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0.4 mg/kg 0.0 mg/kg
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activit
y (uC
i/mL)
0.4 mg/kg 0.0 mg/kg
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (
uCi/mL)
0.4 mg/kg 0.0 mg/kg
L R
0.4 mg/kg 0.0 mg/kgAT47
AT57
AT97
AU18
AU21
A B
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
6
0 2000 4000 6000time (s)
activity (
uCi/mL)
0
1
2
3
4
5
0 2000 4000 6000time (s)
activity (
uCi/mL)
0.4 mg/kg 0.0 mg/kg
Fig. 23. PARAMETER ESTIMATION: Time activity curves from a multiple injection study of a dopamine D2
receptor ligand in rhesus15
Fig. 19 ASTHMA: Glucose metabolism in inflammation in a rat lung10
Fig. 20 MULTIPLE SCLEROSIS: Microglial cell activation in white matter in
response to zymosan in rat11
INFLAMMATION
Fig. 21 OPIOID RECEPTORS: Kappa
opioid receptor availability in parrot
brain6
PAIN
Fig. 22 AVIAN VETERINARY
ANALGESIA: Increased glucose metabolism in
response to experimental arthritis in
parrot6
Fig. 15 STEM CELL THERAPY: Dopamine synthesis in a rhesus model pre- and post- unilateral
lesion13
Fig. 16 NEURODEGENERATION: Rat model of striatal
neurodegneration for pre- (left) and post- (right) stem cell treatment (first image from the microPET P4, 2002)
Fig. 18 L-DOPA: Recovery of AAAD activity in a rhesus model7
Fig. 17 GENE THERAPY: Dopamine synthesis pre- and post- lentiviral delivery of GDNF in a unilateral lesion rhesus model8
PARKINSON’S DISEASE
Fig. 7 CHILDHOOD ANXIETY: Dopamine D2 receptors in rhesus1
MOOD DISORDERS
Fig. 9 SEXUAL BEHAVIOR: Glucose metabolism in female marmosets
Fig. 8 CHILDHOOD ANXIETY: Glucose metabolism in rhesus9
Fig. 10 PRENATAL ALCOHOL EXPOSURE:
glucose metabolism alterations due to a
reversal task in rhesus3
Fig. 11 PRENATAL ALCOHOL EXPOSURE: Serotonin 1A receptors in
rhesus2
ADDICTIVE BEHAVIORS
Fig. 14: EATING BEHAVIORS Dopamine D2 receptor response to deep brain stimulation in
rhesus14
Fig. 12 PRENATAL ALCOHOL EXPOSURE: Image of dopamine transporter in rhesus and time activity curves4
Fig. 13 AMPHETAMINE: Blood flow alteration correlated with dopamine release in rhesus5
Radiotracers Used with the Waisman Center microPET
Design Logistics Radiochemistry Scanner Analysis
PET
Related Documents
![MicroPET/CTImagingof[18F]-FEPPAintheNonhumanPrimate ...downloads.hindawi.com/archive/2012/261640.pdf · 2019. 7. 31. · including nonhuman primates (NHP) [12–14]. In order to obtain](https://static.cupdf.com/doc/110x72/5ff9aa3eae70605aac1dd15e/micropetctimagingof18f-feppainthenonhumanprimate-2019-7-31-including.jpg)
